Michael J. Robertson

A Phase II Study of Rituximab and Gemcitabine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase I/II Study of CHOP plus Ontak, an Interleukin-2 Fusion Toxin for Patients with Peripheral T-cell Non-Hodgkin’s Lymphomas